This site is intended for patients and caregivers.
Disclaimer | Privacy Policy | Contact Us |
VYVGART and VYVGART Hytrulo are registered trademarks of argenx.
For U.S. audiences only.
“When I talk to my patients about self-injection using the VYVGART Hytrulo prefilled syringe, they have questions. I’m passionate about listening to their unique challenges and goals, and providing answers that help them understand their treatment choices. And now, I’m happy to share a few answers with you, too.”
A: Unlike treatments that require visits to an infusion center, VYVGART Hytrulo can be self-injected at home, or wherever you go using the prefilled syringe.* It’s a subcutaneous injection, meaning it’s injected under the skin, and takes about 20-30 seconds to inject.* That said, you can still get VYVGART Hytrulo injections from a healthcare provider in a doctor’s office or clinic, if that’s what you prefer.
A: This is a common question! You’ll get in-person training at home or at your doctor’s office until you’re ready to inject on your own. The same goes for your caregiver, if they’ll be giving the injections. And you’ll get a demonstration kit to help you learn, with an empty syringe and a block to practice on.
A: VYVGART Hytrulo is given in treatment cycles. Each treatment cycle is 4 treatments, 1 given each week, with a personalized break between each cycle. You and your doctor will decide the length of your break based on your symptoms and side effects.
Here’s an example of how that can work. I might start a patient with a break of 4 weeks between treatment cycles. Then, if their symptoms aren’t returning yet after 4 weeks, we talk about extending that break. We keep an eye on their symptoms as we go, and tailor their break to their needs. VYVGART Hytrulo allows us the flexibility to do that.
2018: The first phase 3 clinical trial for VYVGART for intravenous (IV) infusion begins
2021: The FDA approves VYVGART for IV infusion, the first treatment of its kind for adults with anti-AChR antibody positive gMG
2023: The FDA approves VYVGART Hytrulo for subcutaneous injection
2025: VYVGART Hytrulo becomes available as a prefilled syringe for self-injection
Dr. Durrani is a paid spokesperson.
*Please see Patient Information. Follow appropriate administration steps and storage and handling guidance in the Instructions for Use. Monitor for signs and symptoms of an allergic reaction for at least 30 minutes after injection. If an allergic reaction occurs, you should seek medical attention.
AChR=acetylcholine receptor
Do not take VYVGART if you are allergic to efgartigimod alfa or any of the ingredients in VYVGART. Do not take VYVGART HYTRULO if you are allergic to efgartigimod alfa, hyaluronidase, or any of the ingredients in VYVGART HYTRULO. VYVGART or VYVGART HYTRULO can cause serious allergic reactions and a decrease in blood pressure leading to fainting.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Allergic reactions (hypersensitivity reactions). VYVGART or VYVGART HYTRULO can cause allergic reactions that can be severe. These reactions can happen during, shortly after, or weeks after your VYVGART infusion or VYVGART HYTRULO injection. Tell your healthcare provider or get emergency help right away if you have any of the following symptoms of an allergic reaction with VYVGART or VYVGART HYTRULO:
An additional symptom of an allergic reaction with VYVGART HYTRULO can include hives.
These are not all the possible side effects of VYVGART or VYVGART HYTRULO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
VYVGART and VYVGART HYTRULO are both prescription medicines used to treat adults with generalized myasthenia gravis (gMG).
It is not known if VYVGART or VYVGART HYTRULO is safe and effective in children.
Please see full Prescribing and Patient Information for VYVGART HYTRULO for subcutaneous injection and full Prescribing Information for VYVGART for IV infusion.
VYVGART Hytrulo is available as a single-dose subcutaneous injection containing: 200 mg/mL of efgartigimod alfa and 2,000 U/mL of hyaluronidase per prefilled syringe, or 180 mg/mL of efgartigimod alfa and 2,000 U/mL of hyaluronidase per vial. VYVGART is available as a single-dose injection for intravenous use containing 400 mg/20 mL of efgartigimod alfa-fcab per vial.
Do not take VYVGART if you are allergic to efgartigimod alfa or any of the ingredients in VYVGART. Do not take VYVGART HYTRULO if you are allergic to efgartigimod alfa, hyaluronidase, or any of the ingredients in VYVGART HYTRULO. VYVGART or VYVGART HYTRULO can cause serious allergic reactions and a decrease in blood pressure leading to fainting.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Allergic reactions (hypersensitivity reactions). VYVGART or VYVGART HYTRULO can cause allergic reactions that can be severe. These reactions can happen during, shortly after, or weeks after your VYVGART infusion or VYVGART HYTRULO injection. Tell your healthcare provider or get emergency help right away if you have any of the following symptoms of an allergic reaction with VYVGART or VYVGART HYTRULO:
An additional symptom of an allergic reaction with VYVGART HYTRULO can include hives.
These are not all the possible side effects of VYVGART or VYVGART HYTRULO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
VYVGART and VYVGART HYTRULO are both prescription medicines used to treat adults with generalized myasthenia gravis (gMG).
It is not known if VYVGART or VYVGART HYTRULO is safe and effective in children.
Please see full Prescribing and Patient Information for VYVGART HYTRULO for subcutaneous injection and full Prescribing Information for VYVGART for IV infusion.
VYVGART Hytrulo is available as a single-dose subcutaneous injection containing: 200 mg/mL of efgartigimod alfa and 2,000 U/mL of hyaluronidase per prefilled syringe, or 180 mg/mL of efgartigimod alfa and 2,000 U/mL of hyaluronidase per vial. VYVGART is available as a single-dose injection for intravenous use containing 400 mg/20 mL of efgartigimod alfa-fcab per vial.